Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Medicines Nav

Medicines

Research Nav

Science

Responsibility Nav

Our Purpose

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News Press Release Archive

Press Release Archive

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Press Release Archive

Year

Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 21, 2023

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences

September 13, 2023

Jazz Pharmaceuticals Announces Key Update to Leadership Team

September 12, 2023

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

September 11, 2023

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference

August 24, 2023

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance

August 9, 2023

Jazz Pharmaceuticals enters into Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Rylaze®, helping address the unmet need of acute lymphoblastic leukemia and lymphoblastic lymphoma patients across Canada

August 2, 2023

Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023

July 26, 2023

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

July 21, 2023

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

June 2, 2023

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 508

About Nav

About

Medicines Nav

Medicines

Research Nav

Science

Responsibility Nav

Our Purpose

IR Nav

Investors

© 2023 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
Terms of Use
Social Media Global Guidelines
Cookie Policy
Sitemap